• Study to evaluate the safety and tolerability of KIT2014, an inhaled peptide therapy designed to enhance Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function, act […]
Series C financing led by Decheng Capital and supported by a syndicate of new and existing investors including Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon […]